New pharmaceuticals for unresectable Or metastatic malignant melanoma

NEW PHARMACEUTICALS FOR UNRESECTABLE OR METASTATIC MALIGNANT MELANOMA

This KCE has read for you was prepared by Lorena San Miguel and Nadia Benahmed

pdf fileDOWNLOAD THE FULL VERSION OF THIS KCE HAS READ FOR YOU (232 KB)

KEY MESSAGES 

  • The Norwegian Knowledge Centre for the Health Services assessed in November 2015 the effectiveness and cost-effectiveness of seven new drugs for the treatment of unresectable or metastatic malignant melanoma in the adult population. Their review included evidence from 17 RCTs.
     
  • For overall survival (over a 2 year time horizon), nivolumab or pembrolizumab as monotherapies as well as the combinations of nivolumab+ipilimumab, 
    vemurafenib+cobimetinib and dabrafenib+trametinib have the highest probabilities of being superior to the other treatment strategies.

     
  • For safety, nivolumab and pembrolizumab have the lowest probability of serious adverse events but the quality of the evidence was rated as low.
     
  • The cost-effectiveness evaluation including all interventions showed that at list prices in Norway, all new treatments had ICERs above € 100 000 per QALY.
What is KCE has read for you?

inter

KCE has read for you synthesises a recently published high-quality systematic review or health technology assessment with relevance for the Belgian health system.

The original publication was appraised and contextualised by KCE researchers. KCE has read for you is not based on original research conducted by KCE.

More details on methodology can be found on the KCE website.

doc

This document includes

  • Key findings of the publication under evaluation
  • A contextualisation within the Belgian healthcare system
Cross

Not included

  • Recommendations
  • Detailed descriptions

Band

Trustworthy original publication

The methodological quality of the systematic review was assessed with the AMSTAR tool.

CONTACT PERSON
Gudrun BRIAT (NL)
Communication Manager for the KCE
Published on: 
2016/05/25